We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adverum Biotechnologies Inc | NASDAQ:ADVM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.53 | -5.13% | 9.81 | 3.92 | 11.19 | 10.17 | 9.60 | 10.17 | 200,543 | 21:05:19 |
Individuals can participate in the conference call by dialing 1-866-420-8347 (domestic) or 1-409-217-8241 (international) and refer to the “Adverum Biotechnologies Third Quarter 2019 Earnings Call.” The webcast will be accessible under Events and Presentations in the Investors section of the Company's website. The archived audio webcast will be available on the Adverum website following the call and will be available for 30 days.
About Adverum Biotechnologies, Inc.Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Investors:Myesha LacyAdverum BiotechnologiesVice President, Investor Relations and Corporate Communicationsmlacy@adverum.com1-650-304-3892
Media:Cherilyn Cecchini, M.D.Account Supervisorccecchini@lifescipublicrelations.com 1-646-876-5196
1 Year Adverum Biotechnologies Chart |
1 Month Adverum Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions